These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38341039)

  • 1. Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.
    Hassanein M; El Naggar A; Al Sheikh A; Djaballah K; Saeed M; Melas-Melt L; AlSifri S
    Diabetes Res Clin Pract; 2024 Mar; 209():111567. PubMed ID: 38341039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study.
    Hassanein M; Malek R; Shaltout I; Sahay RK; Buyukbese MA; Djaballah K; Pilorget V; Coudert M; Al Sifri S;
    Diabetes Metab Syndr; 2023 Feb; 17(2):102707. PubMed ID: 36680967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
    Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study.
    Hassanein M; Buyukbese MA; Malek R; Pilorget V; Naqvi M; Berthou B; Shaltout I; Kumar Sahay R
    Diabetes Res Clin Pract; 2020 Aug; 166():108189. PubMed ID: 32360709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study.
    Malik RA; Elhadd T; Alattar A; Al Shaikh A; Al Randi M; Arora R; Al-Sifri S; Akil Y; Magdy A; Naqvi M; Hassanein M
    Diabetes Ther; 2022 Mar; 13(3):569-581. PubMed ID: 35239165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM).
    Hassanein M; Al Awadi FF; El Hadidy KES; Ali SS; Echtay A; Djaballah K; Dessapt-Baradez C; Khazaal FAK; Abu-Hijleh MO; Al Shaikh A; Gharbi MEH; Shehadeh N; Bennakhi A; Al Arouj M
    Diabetes Res Clin Pract; 2019 May; 151():275-284. PubMed ID: 30825560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitude and safety of patients with diabetes observing the Ramadan fast.
    Ba-Essa EM; Hassanein M; Abdulrhman S; Alkhalifa M; Alsafar Z
    Diabetes Res Clin Pract; 2019 Jun; 152():177-182. PubMed ID: 30946851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between pre-ramadan glycemic control and subsequent glucose fluctuation during fasting in adolescents with Type 1 diabetes.
    Afandi B; Kaplan W; Al Hassani N; Hadi S; Mohamed A
    J Endocrinol Invest; 2017 Jul; 40(7):741-744. PubMed ID: 28239763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting during the holy month of Ramadan among older children and adolescents with type 1 diabetes in Kuwait.
    Mohamed K; Al-Abdulrazzaq D; Fayed A; El Busairi E; Al Shawaf F; Abdul-Rasoul M; Shaltout AA
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):843-849. PubMed ID: 31318694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
    Uddin MF; Khan MA; Selim S; Sultana N; Sayem MA; Iftekhar MM; Habib MB; Akter N; Khan S
    J Comp Eff Res; 2024 Feb; 13(2):e230132. PubMed ID: 38294337
    [No Abstract]   [Full Text] [Related]  

  • 12. A Real-World Observational Study of Gla-300 in Adults with Type 2 Diabetes Who Fast During Ramadan in the South Asia Region: A Subgroup Analysis of the ORION Study.
    Hassanein M; Sahay R; Hasan MI; Hussain A; Mittal V; Mohammed R; Shaikh Z; Farishta F; Mohanasundaram S; Naqvi M; Nair A; Ali Z
    Diabetes Ther; 2022 Apr; 13(4):747-759. PubMed ID: 35286607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Ramadan fasting: A randomised controlled trial for people with type 2 diabetes during Ramadan applying the principles of the ADA/EASD consensus.
    Ibrahim M; Barker MM; Ahmad E; Ahmed A; Annabi FA; Ba-Essa EM; Davies MJ; Houeiss P; Iraqi H; Masood SN; Mimouni-Zerguini S; Shaikh S; Tantawi H; Tuomilehto J
    Diabetes Metab Res Rev; 2023 Mar; 39(3):e3604. PubMed ID: 36547366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study.
    Raza SA; Akram J; Aamir AH; Ahmedani Y; Hassan MI
    Diabetes Res Clin Pract; 2021 Nov; 181():109086. PubMed ID: 34634390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
    Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting.
    Yousuf S; Ahmedani MY
    Diabetes Metab Syndr; 2022 Nov; 16(11):102633. PubMed ID: 36279701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Ramadan fasting on metabolic profile among type 2 diabetes mellitus patients: A meta-analysis.
    Tahapary DL; Astrella C; Kristanti M; Harbuwono DS; Soewondo P
    Diabetes Metab Syndr; 2020; 14(5):1559-1570. PubMed ID: 32947756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.